QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

BVS

QT71Bioventus Inc.
NASDAQ·Healthcare·Medical - Devices·USA
Latest market price
8.71
+0.17+1.99%
OverviewShort InterestFilings
BVSQT71Bioventus Inc.·NASDAQ
OverviewShort InterestFilings
8.71+1.99%
TA
Loading chart...
Screen all →
ABT-0.10%$88.41ISRG+1.14%$406.78SYK+2.21%$307.80MDT+1.54%$79.34BSX+0.76%$45.29EW+0.78%$87.36DXCM+1.74%$72.47RMD+1.26%$188.63
Snapshot
Index-P/E20.18EPS (ttm)0.42
Insider Own29.64%
Shs Outstand67.75M
Perf Week0.35%
Market Cap578.57MForward P/E9.61EPS next Y0.91Insider Trans1.69%Shs Float-Perf Month-18.29%
Enterprise Value814.80MPEG0.00EPS next Q0.21Inst Own-Short Float-Perf Quarter-3.22%
Income28.70MP/S1.00EPS this Y83.45%Inst Trans-Short Ratio-Perf Half Y15.82%
Sales576.32MP/B3.04EPS next Y16.77%ROA4.38%Short Interest-Perf YTD17.07%
Book/sh-P/C5.58EPS next 5Y12.19%ROE16.27%52W High11.25 -22.58%Perf Year37.17%
Cash/sh-P/FCF5.75EPS past 3/5Y-ROIC11.77%52W Low5.81 49.91%Perf 3Y-
Dividend Est.-EV/EBITDA7.89Sales past 3/5Y-Gross Margin67.78%Volatility2.18% 3.41%Perf 5Y-
Dividend TTM-EV/Sales1.41EPS Y/Y TTM-Oper. Margin10.64%ATR (14)0.44Perf 10Y-
Dividend Ex-Date-Quick Ratio1.13Sales Y/Y TTM-Profit Margin4.94%RSI (14)43.95Recom2.33
Dividend Gr. 3/5Y-Current Ratio1.69EPS Q/Q87.50%SMA20-0.66%Beta0.96Target Price14.00
Payout0.00%Debt/Eq1.44Sales Q/Q-SMA50-9.37%Rel Volume1.79Prev Close8.54
Employees930LT Debt/Eq-EarningsAug 05SMA2006.41%Avg Volume591.03KPrice8.71
IPO DateFeb 11, 2021Option/ShortYes / YesEPS/Sales Surpr.66.67% 1.54%Net Debt/EBITDA2.29Volume1,060,181Change1.99%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-16-26ReiteratedCanaccord GenuityBuy$12 → $15
Feb-09-26InitiatedBarringtonOutperform$13
May-07-25ReiteratedCraig-HallumBuy$17 → $15
Dec-17-24UpgradeJP MorganUnderweight → Neutral
Oct-01-24ReiteratedCanaccord GenuityBuy$8.00 → $12
Aug-07-24ReiteratedCraig-HallumBuy$9.00 → $12
Mar-13-24ReiteratedCraig-HallumBuy$9.00
Dec-07-23UpgradeCanaccord GenuityHold → Buy
Nov-30-22ReiteratedGoldman SachsNeutral$2.50
Nov-22-22DowngradeCraig-HallumBuy → Hold
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Insider Trading Volume
$9.57$8.55$7.52$6.49$5.47● Close Price0.00K32.81K65.63K98.44K131.25KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
McMurry-Heath MichelleDirectorJun 02 '26Option Exercise0.0064,564077,279Jun 04 12:00 AM
Ladone Mary KayDirectorJun 02 '26Option Exercise0.0064,5640111,263Jun 04 12:00 AM
HAWKINS WILLIAM ADirectorJun 02 '26Option Exercise0.0079,5780297,640Jun 04 12:00 AM
Cowdy Philip G.DirectorJun 02 '26Option Exercise0.0064,564043,982Jun 04 12:00 AM
Beyer PatDirectorJun 02 '26Option Exercise0.0064,5640108,718Jun 04 12:00 AM
SUTTER MARTIN Pdirector, 10 percent owner:Jun 02 '26Option Exercise0.0064,5640117,523Jun 04 12:00 AM
STALNECKER SUSAN MDirectorJun 02 '26Option Exercise0.0064,5640138,239Jun 04 12:00 AM
NOHRA GUY PDirectorJun 02 '26Option Exercise0.0064,5640148,892Jun 04 12:00 AM
Bartholdson John A.director, 10 percent owner:Jun 02 '26Option Exercise0.0064,5640111,902Jun 04 12:00 AM
NEELS GUIDO JDirectorJun 02 '26Option Exercise0.0064,5640117,523Jun 04 12:00 AM
D'Adamio AnthonySVP & General CounselApr 10 '26Option Exercise0.0019,8500157,967Apr 14 12:00 AM
Singleton Mark LeonardSVP & CFOApr 10 '26Option Exercise0.0026,0000182,981Apr 14 12:00 AM
CHURCH KATRINA JSVP & Chief Compliance OfficerApr 10 '26Option Exercise0.008,600066,032Apr 14 12:00 AM
Singleton Mark LeonardSVP & CFOMar 20 '26Option Exercise0.0037,2500178,072Mar 24 12:00 AM
Singleton Mark LeonardSVP & CFOMar 13 '26Option Exercise0.0027,0000165,312Mar 17 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR